Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis

Clinical and Experimental Nephrology

Volumn 13, Issue 1, 2009, Pages 85-88

  Miura, Naoto ^a   Mizuno, Natsuko ^a   Aoyama, Ryuhei ^a   Kitagawa, Wataru ^a   Yamada, Harutaka ^a   Nishikawa, Kazuhiro ^a   Imai, Hirokazu ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute renal failure; Bisphosphonate; Focal segmental glomerulosclerosis; Nephrotic syndrome

Indexed keywords

ALENDRONIC ACID; PREDNISOLONE;

ACUTE KIDNEY FAILURE; ADULT; ANAMNESIS; APHERESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG EFFICACY; DRUG WITHDRAWAL; FOCAL GLOMERULOSCLEROSIS; HEMODIALYSIS; HUMAN; KIDNEY BIOPSY; LABORATORY TEST; MALE; NEPHROTIC SYNDROME; PROTEIN URINE LEVEL; PROTEINURIA;

ADMINISTRATION, ORAL; ALENDRONATE; BLOOD COMPONENT REMOVAL; BONE DENSITY CONSERVATION AGENTS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; KIDNEY FAILURE, ACUTE; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; OSTEOPOROSIS; PROTEINURIA; RENAL DIALYSIS; STEROIDS; TREATMENT OUTCOME;

EID: 59449084227     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-008-0078-x     Document Type: Article

References (11)

1. MJ Roger S Gordon HL Benford 2000 Cellular and molecular mechanisms of action of bisphosphonates Cancer 88 Suppl 12 2961 78
2. F Lioté B Boval-Boizard P Fritz D Kuntz 1995 Lymphocyte subsets in pamidronate-induced lymphopenia Br J Rheumatol 34 993 5
3. T Tanvetyanon PJ Stiff 2006 Management of the adverse effects associated with intravenous bisphosphonates Ann Oncol 17 897 907
4. GS Markowitz GB Appel PL Fine AZ Fenves NR Loon S Jagannath J Kuhn AD Dratch VD D'Agati 2001 Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate J Am Soc Nephrol 12 1164 72
5. JD Stratton P Warwicker 2002 Relapse of nephrotic syndrome triggered by bisphosphonates Nephrol Dial Transplant 17 1856 7
6. DM Black AV Schwartz KE Ensrud JA Cauley S Levis SA Quandt S Satterfield RB Wallace DC Bauer L Palermo LE Wehren A Lombardi AC Santora SR Cummings for the FLEX research group 2006 Effects of continuing or stopping alendronate after 5 years of treatment. The fracture intervention trial long-term extension (FLEX): A randomized trial JAMA 296 2927 38
7. RNJ de Nijs JW Jacobs WF Lems RF Laan A Algra AM Huisman E Buskens CED de Laet ACM Oostveen PPMM Geusens GAW Bruyn BAC Dijkmans 2006 Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis N Engl J Med 355 675 84
8. H Dijkman B Smeets J van der Laak E Steenbergen J Wetzels 2005 The parietal epithelial cell is crucially involved in human idiopathic focal segmental glomerulosclerosis Kidney Int 68 1562 72
9. T Asano F Niimura I Pastan AB Fogo I Ichikawa T Matsusaka 2005 Permanent genetic tagging of podocytes: Fate of injured podocytes in a mouse model of glomerular sclerosis J Am Soc Nephrol 16 2257 62
10. CB Marshall SJ Shankland 2006 Cell cycle and glomerular disease: A minireview Nephron Exp Nephrol 102 e39 48
11. J Pascual J Torrealba J Myers S Tome M Samaniego A Musat A Djamali 2007 Collapsing focal segmental glomerulosclerosis in a liver transplant recipient on alendronate Osteoporos Int 18 1435 8